Synthesis, characterization, and molecular docking analysis of novel benzimidazole derivatives as cholinesterase inhibitors

Bioorganic Chemistry

Volumn 49, Issue , 2013, Pages 33-39

  Yoon, Yeong Keng ^a   Ali, Mohamed Ashraf ^a,b,c   Wei, Ang Chee ^a   Choon, Tan Soo ^a   Khaw, Kooi Yeong ^d   Murugaiyah, Vikneswaran ^d   Osman, Hasnah ^a   Masand, Vijay H ^e  

^a SCHOOL OF PHYSICS   (Malaysia)

^b Alwar Pharmacy College   (India)

^c Sunrise University   (India)

^d SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^e Vidya Bharati College   (India)

Author keywords

Acetylcholinesterase; Alzheimer's Disease; Benzimidazoles; Butyrylcholinesterase

Indexed keywords

ACETYLCHOLINESTERASE; BENZIMIDAZOLE DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE; BENZIMIDAZOLE;

ARTICLE; CHOLINESTERASE INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; LIPOPHILICITY; MASS SPECTROMETRY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; SYNTHESIS;

BENZIMIDAZOLES; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885091255     PISSN: 00452068     EISSN: 10902120     Source Type: Journal    
DOI: 10.1016/j.bioorg.2013.06.008     Document Type: Article

References (24)

1. K. Blennow, M.J. de Leon, H. Zetterberg, Alzheimer's disease, Lancet 368 (2006) 387-403. (Pubitemid 44108123)
2. B.M. McGleenon, K.B. Dynan, A.P. Passmore, Acetylcholinesterase inhibitors in Alzheimer's disease, Br. J. Clin. Pharmacol. 48 (4) (1999) 471-480. (Pubitemid 29454225)
3. T. Mohamed, P.P.N. Rao, Alzheimer's disease: emerging trends in small molecule therapies, Curr. Med. Chem. 18 (28) (2011) 4299-4320.
4. S.B. Dunnett, H.C. Fibiger, Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia, Prog. Brain Res. 98 (1993) 413-420. (Pubitemid 23305674)
5. M. Weinstock, Possible role of the cholinergic system and disease models, J. Neural Transm. Suppl. 49 (1997) 93-102. (Pubitemid 27351477)
6. V. Pejchal, S. Stepankova, Z. Padelkova, A. Imramovsky, J. Jampilek, 1,3-Substituted imidazolidine-2,4,5-triones: synthesis and inhibition of cholinergic enzymes, Molecules 16 (2011) 7565-7582.
7. M. Mader, A. de Dios, C. Shih, B.D. Anderson, Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties, Bioorg. Med. Chem. Lett. 18 (2008) 179-183.
8. B.E. Evans, K.E. Rittle, M.G. Bock, R.M. Dipardo, R.M. Freidinger, W.L. Whitter, G.F. Lundell, D.F. Veber, S. Anderson, Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists, J. Med. Chem. 42 (1988) 2235-2246. (Pubitemid 19001640)
9. J.R. Kumar, J. Jawahar, D.P. Pathak, Synthesis of benzimidazole derivatives: as anti-hypertensive agents, E-Journal Chem. 3 (13) (2006) 278-285.
10. G. Komazin, R.G. Ptak, B.T. Emmer, L.B. Townsend, J.C. Drach, Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs, Nucleosides, Nucleotides Nucleic Acids 22 (2003) 1725-1727. (Pubitemid 37139484)
11. M. Pieroni, S.M. Tipparaju, S. Lun, Y. Song, A.W. Sturm, W.R. Bishai, A.P. Kozikowski, Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB, ChemMedChem 6 (2011) 334-342.
12. C. Kus, Synthesis of new substituted 6-(morpholin-4-yl)-1H-benzimidazole derivatives, Turk. J. Chem. 26 (2002) 559-564.
13. K.Y. Yeong, M.A. Ali, R. Ismail, M.M. Rosli, H.K. Fun, Ethyl 1-[2-(morpholin-4-yl)ethyl]-2-[4-(morpholin-4-yl)phenyl]-1H-1, 3-benzimidazole-5-carboxylate, Acta Crystallogr. E E67 (2011) o1772.
14. K.Y. Yeong, M.A. Ali, S.C. Tan, S.I.K. Asik, I.A. Razak, Ethyl 2-(1,3-benzodioxol-5-yl)-1-[3-(1H-imidazol-1-yl)propyl]-1H-benzimidazole-5- carboxylate, Acta Crystallogr. E E68 (2012) o247.
15. W. Zeller, A.S. Kiselyov, J. Singh, Regiospecific synthesis of 3-alkyl-4-hydroxybenzimidazoles as intermediates for an expedient approach to potent EP3 receptor antagonists, Tetrahedron Lett. 51 (2010) 1380-1382.
16. C. Gill, G. Jadhav, M. Shaikh, R. Kale, A. Ghawalkar, D. Nagargoje, M. Shiradkar, Clubbed [1,2,3] triazoles by fluorine benzimidazole: a novel approach to H37Rv inhibitors as a potential treatment for tuberculosis, Bioorg. Med. Chem. Lett. 18 (2008) 6244-6247.
17. T. Roth, M.L. Morningstar, P.L. Boyer, S.H. Hughes, R.W. Buckheit, C.J. Michejda, Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles, J. Med. Chem. 40 (1997) 4199-4207. (Pubitemid 28042301)
18. G.L. Ellman, K.D. Courtney, V. Andres, R.M. Featherstone, A new and rapid colorimetric determination of acetylcholinesterase activities, Biochem. Pharmacol. 7 (1961) 88-95.
19. S.Y. Chiou, C.F. Huang, M.T. Hwang, G. Lin, Comparison of active sites of butyrylcholinesterase and acetylcholinesterase based on inhibition by geometric isomers of benzene-di-N-substituted carbamates, J. Biochem. Mol. Toxicol. 5 (2009) 303-308.
20. N.H. Greig, D.K. Lahiri, K. Sambamurthi, Butyrylcholinesterase: an important new target in Alzheimer's disease therapy, Int. Psychogeriatr. 14 (2002) 77-91. (Pubitemid 36206092)
21. M.A. Ali, R. Ismail, S.C. Tan, R.S. Kumar, M. Asad, A.I. Almansour, K.Y. Yeong, C.W. Ang, K. Elumalai, S. Pandian, Alzheimer diseases: substituted spiro [2.3'] oxindolespiro [3.2'']-5, 6-dimethoxy-indane-1'',-one-indolizine analogue as inhibitors of acetylcholinesterase, Med. Chem. 2 (2012) 1-4.
22. P. Szymanski, M. Markowicz, E. Mikiciuk-Olasik, Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors, Bioorg. Chem. 39 (2011) 138-142.
23. S. Auriacombe, J.J. Pere, Y. Loria-Kanza, B. Vellas, Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepenzil, Curr. Med. Res. Opin. 18 (3) (2002) 129-138. (Pubitemid 34665750)
24. G. Kryger, I. Silman, J.L. Sussman, Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design for the new anti-Alzheimer drugs, Structure 7 (1999) 297-307. (Pubitemid 29159689)